---
title: "TRANSTHERA-B plans to implement full circulation of H shares"
description: "TRANSTHERA-B plans to apply to the China Securities Regulatory Commission on October 20, 2025, to convert 44.9711 million domestic shares held by 10 shareholders into H shares, accounting for approxim"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261850747.md"
published_at: "2025-10-20T09:52:09.000Z"
---

# TRANSTHERA-B plans to implement full circulation of H shares

> TRANSTHERA-B plans to apply to the China Securities Regulatory Commission on October 20, 2025, to convert 44.9711 million domestic shares held by 10 shareholders into H shares, accounting for approximately 11.33% of the total issued shares. This conversion requires relevant approvals and must meet the qualifications for listing and trading on the Main Board of the Stock Exchange

According to the Zhitong Finance APP, TRANSTHERA-B (02617) announced that on October 20, 2025, the company's board of directors considered and approved the application to the China Securities Regulatory Commission to convert 44.9711 million domestic shares held by 10 shareholders into H shares of the company, accounting for approximately 11.33% of the total issued shares of the company as of the date of this announcement. Upon obtaining all relevant approvals (including those from the China Securities Regulatory Commission and the Stock Exchange) and complying with all applicable laws, regulations, and rules, these domestic shares will be converted into H shares and will qualify for listing and trading on the main board of the Stock Exchange

### Related Stocks

- [02617.HK - TRANSTHERA-B](https://longbridge.com/en/quote/02617.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 港股異動：基石投資者解禁引發擔憂，藥捷安康-B 股價暴跌 16.36% | 藥捷安康-B 跌 16.36%；信達生物漲 0.92%，成交額達到 2.51 億港幣；三生製藥漲 1.68%，成交額達到 1.83 億港幣；榮昌生物漲 0.92%，成交額達到 1.37 億港幣；百濟神州漲 0.43%，市值達到 2889 億 | [Link](https://longbridge.com/en/news/270561769.md) |
| 港股異動：藥捷安康-B 漲 16.21%，資金流向活躍，板塊趨勢引發市場關注？ | 藥捷安康-B 漲 16.21%；三生製藥跌 1.44%，成交額達到 1.3 億港幣；信達生物跌 1.01%，成交額達到 1.17 億港幣；康方生物跌 1.52%，成交額達到 70.04 百萬港幣；百濟神州跌 1.14%，市值達到 2799  | [Link](https://longbridge.com/en/news/271050704.md) |
| 阿里及百度等擬被納入中國軍事企業清單 阿里斥毫無依據 ADR 仍較港股高水 | 阿里巴巴、百度等多家中國企業被列入美國政府的軍事企業清單，導致其美股價格下跌。阿里巴巴對此表示強烈反對，稱提議毫無依據，並將採取法律行動。被列入清單的企業還包括藥明康德和比亞迪等。根據新法，美國國防部未來將禁止與這些公司籤訂合同。該清單自  | [Link](https://longbridge.com/en/news/275920335.md) |
| 涉擔保北京項目 買方入稟阻走資 高院下令禁張瑜平妻子轉移亨得利股權 | 亨得利控股前主席張瑜平因擔保北京房地產項目而遭法庭頒發臨時禁制令，禁止轉移約 2.8 億元人民幣資產。張瑜平無償轉讓 7.4 億股亨得利股份予妻子馮稼喬，法庭現已批准買方北京誠義豪泰投資管理有限公司的申請，暫時禁止馮稼喬轉移該股份。張氏家族 | [Link](https://longbridge.com/en/news/275242071.md) |
| Radicant–Numarics 交易：瑞士金融市場監督管理局（Finma）現已介入 | 瑞士金融市場監管局（Finma）正在調查 Radicant 銀行與 Numarics 之間備受爭議的合併，該合併導致了 1.055 億法郎的重大減值。此次合併於 2024 年 10 月 17 日宣佈，旨在提供綜合銀行服務，但未能成功，導致  | [Link](https://longbridge.com/en/news/276324738.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.